本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： ●南京海辰药业股份有限公司（以下简称"公司"）拟将其持有的位于南 京市玄武区盛世华庭凤泽苑 C9 幢 01-02 室房产（评估价值 2855.15 万元） 转让给公司控股股东、实际控制人曹于平先生及姜晓群女士，转让价格总 计 2,950 万元。 证券代码：300584 证券简称：海辰药业 公告编号：2025-037 南京海辰药业股份有限公司 关于向关联方出售房产暨关联交易的公告 议案》。公司独立董事对本次关联交易事项召开了专门会议并发表了同意的审 核意见。 4、本次关联交易未构成《上市公司重大资产重组管理办法》规定的重大资 产重组。根据公司《公司章程》《关联交易决策制度》相关规定，本事项属于 董事会审批权限，无需提交公司股东大会审议。 二、关联交易方基本情况 ●本次交易构成关联交易。本次关联交易不构成重大资产重组，过去 12 个 月内，公司未与曹于平先生及姜晓群女士发生关联交易。 ●本次交易已经公司第四届董事会第二十三次会议、第四届董事会独立董 事 2025 年第二次专门会议、第四届监事会第二十一 ...

证券代码：300584 证券简称：海辰药业 公告编号：2025-035 南京海辰药业股份有限公司 第四届董事会第二十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长曹于平先生召集，会议通知于 2025 年 6 月 27 日通 过电话、电子邮件、专人送达等形式送达至各位董事，董事会会议通知中包括会 议的相关材料，同时列明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2025 年 6 月 30 日在公司会议中心三楼会议室召开，本次 会议采取通讯表决方式召开。 3、本次董事会应出席 7 人，实际出席会议人数为 7 人。 三、备查文件 4、本次董事会由董事长曹于平先生主持，公司部分高级管理人员、证券部 工作人员列席了会议。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《公司章程》的有关规定。 二、董事会会议审议情况 会议审议并通过如下议案： 1、审议通过《关于向关联方出售房产暨关联交易的议案》 为增加公司流动资金，提高资产使用效率，董事会同意公司将持有的位于南 京 ...

证券代码：300584 证券简称：海辰药业 公告编号：2025-038 南京海辰药业股份有限公司 2025 年第一次临时股东大会通知公告的更正公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、更正补充事项涉及的具体内容和原因 1、股东大会届次：2025年第一次临时股东大会 2、股东大会的召集人：董事会 3、会议召开的合法、合规性：本次股东大会的召开符合《公司法》《深圳证 券交易所创业板股票上市规则》等有关法律、法规、部门规章、规范性文件及《公 司章程》的规定。 4、会议召开的日期、时间 （1）现场会议召开时间：2025年7月15日（星期二）上午10:00； （2）网络投票时间：2025年7月15日（星期二）； 其中，通过深圳证券交易所交易系统进行网络投票的时间为：2025年7月15 日（星期二）9:15-9:25、9:30-11:30；通过深圳证券交易所互联网投票系统进 行投票的具体时间为：2025年7月15日（星期二）9:15-11:30。 5、会议的召开方式：采取现场表决与网络投票相结合的方式 南京海辰药业股份有限公司（以下简称"公司"）于 202 ...

Group 1 - The company held a supervisory board meeting where the agenda included the review and approval of certain proposals related to corporate governance and compliance with legal regulations [1][2] - The supervisory board approved a proposal to allow the board's audit committee to exercise the powers of the supervisory board as per the revised Company Law and other relevant regulations, pending approval from the upcoming shareholders' meeting [1][2] - The proposal requires a two-thirds majority vote from shareholders at the 2025 first extraordinary general meeting to be implemented [2] Group 2 - The meeting was conducted through various communication methods, ensuring all members received the necessary materials and information regarding the meeting [1] - The supervisory board will continue to fulfill its responsibilities until the audit committee officially assumes the supervisory board's powers [1] - The company plans to amend its articles of association in conjunction with the establishment of employee representative directors [1]

Meeting Information - The company will hold its first extraordinary general meeting of shareholders for 2025 on July 15, 2025, at 10:00 AM [1][2] - Shareholders can participate in the meeting either in person or through online voting [2][3] Voting Procedures - Online voting will be available on July 15, 2025, from 9:15 AM to 11:30 AM through the Shenzhen Stock Exchange trading system and internet voting system [2][11] - Shareholders must register to vote, and those unable to attend can appoint a proxy to vote on their behalf [3][7] Agenda Items - The meeting will discuss several proposals, including the election of the fifth board of directors and amendments to various governance documents [5][6] - Proposals requiring cumulative voting include the election of three non-independent directors and three independent directors [6] Registration Requirements - Corporate shareholders must provide specific documentation for registration, while individual shareholders need to present their identification and securities account information [3][7] - Remote shareholders can register via mail, fax, or email, with a deadline of July 11, 2025 [3][7] Contact Information - Shareholders can contact the company's securities department for inquiries regarding the meeting [7][8]

Group 1 - The nominee, Lu Tao, has been proposed as a candidate for the independent director of Nanjing Haichen Pharmaceutical Co., Ltd.'s fifth board of directors [1] - The nomination was made after a thorough understanding of the nominee's professional background, education, qualifications, work experience, and any significant dishonesty records [1] - The nominee has agreed in writing to serve as an independent director candidate [1] Group 2 - The nominee has passed the qualification review by the nomination committee or a special meeting of independent directors [2] - There are no conflicts of interest or other relationships that may affect the nominee's independent performance [2] - The nominee meets the qualifications and independence requirements set forth by relevant laws and regulations [2][3] Group 3 - The nominee has participated in training and obtained relevant certification recognized by the stock exchange [5] - The nominee's appointment as an independent director will not violate the relevant provisions of the Civil Servant Law of the People's Republic of China [5] - The nominee does not have any disqualifying conditions as per the Company Law of the People's Republic of China [2][5] Group 4 - The nominee has the necessary knowledge of the operation of listed companies and relevant laws and regulations, with at least five years of relevant work experience [5] - The nominee and their immediate family members do not hold positions in the company or its subsidiaries [6] - The nominee is not a direct or indirect shareholder holding more than 1% of the company's issued shares [6][7] Group 5 - The nominee has not been subject to any disqualifying actions by the China Securities Regulatory Commission [8] - The nominee has not been penalized for securities-related crimes in the last 36 months [8] - The nominee has not been publicly criticized by the stock exchange three times or more in the last 36 months [9]

Core Viewpoint - Nanjing Hailin Pharmaceutical Co., Ltd. is preparing for the election of its fifth board of directors, following the completion of the fourth board's term, in accordance with relevant laws and regulations [1][2]. Group 1: Board Composition - The fifth board of directors will consist of 7 members, including 4 non-independent directors and 3 independent directors, with one non-independent director elected by the employee representative assembly [2]. - The candidates for the fifth board include Cao Yuping, Cao Xicheng, and Feng Mingsheng as non-independent directors, and Lu Tao, Mao Lingxiao, and Wang Yuchun as independent directors [2][3]. Group 2: Candidate Qualifications - All candidates have been vetted and meet the qualifications required by the Company Law and the company's articles of association [2][5]. - Independent director candidates Lu Tao, Mao Lingxiao, and Wang Yuchun have obtained independent director qualification certificates recognized by the Shenzhen Stock Exchange [2][7][9]. Group 3: Election Process - The election of the fifth board of directors will be submitted to the company's first extraordinary general meeting of 2025 for approval, using a cumulative voting system [2][3]. - The term for the new board members will last for three years from the date of approval at the extraordinary general meeting [3]. Group 4: Candidate Profiles - Cao Yuping, born in 1964, holds a master's degree and has extensive experience in the pharmaceutical industry, currently serving as the chairman and general manager of the company [3][4]. - Cao Xicheng, born in 1994, is a master's degree holder and the son of Cao Yuping, currently serving as a director of the company [5]. - Feng Mingsheng, born in 1978, holds a doctoral degree and is currently the deputy manager of the new drug department [6]. - Lu Tao, born in 1963, is a pharmaceutical expert with a doctoral degree and has served in various academic roles [7]. - Mao Lingxiao, born in 1964, is a senior lawyer with extensive legal experience and currently serves as an independent director [8]. - Wang Yuchun, born in 1956, is a professor of accounting with a master's degree and has served as an independent director for other companies [9].

南京海辰药业股份有限公司董事会 附件：职工代表董事简历 证券代码：300584 证券简称：海辰药业 公告编号：2025-033 南京海辰药业股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京海辰药业股份有限公司（以下简称"公司"）第四届董事会任期即将届 满，根据相关法律法规及《公司章程》关于职工代表董事选举的有关规定，公司 于 2025 年 6 月 23 日在公司会议室召开职工代表大会，经全体与会职工代表审议， 选举褚源红女士为公司第五届董事会职工代表董事（简历详见附件）。 褚源红女士将与公司 2025 年第一次临时股东大会选举产生的三名非职工代 表董事共同组成公司第五届董事会，任期至第五届董事会届满为止。 特此公告。 褚源红女士，1982年出生，中国国籍，无境外永久居留权，本科学历。2018 年毕业于南京大学人力资源管理专业，获管理学学士学位；现任公司人力资源总 监，2003年7月至今，先后任行政人事专员、行政人事主管、人力资源部副经理、 经理等职务；2022年7月至今，担任本公司监事。 截至目前，褚源红女士未持有公司股份，与控股股东、实际控 ...

Core Points - The document outlines the rules for the shareholders' meeting of Nanjing Haichen Pharmaceutical Co., Ltd, ensuring compliance with the Company Law and Securities Law of the People's Republic of China [1][2][3] Group 1: Shareholders' Meeting Procedures - The company must convene shareholders' meetings in accordance with legal and regulatory requirements, ensuring shareholders can exercise their rights [1][2] - Shareholders' meetings can be annual or temporary, with annual meetings held within six months after the end of the previous fiscal year [6][8] - The board of directors is responsible for organizing the meetings and must report to the China Securities Regulatory Commission if unable to convene within the specified timeframe [6][8] Group 2: Voting and Proposals - Proposals for the shareholders' meeting must be within the scope of the meeting's authority and clearly defined [11][12] - Shareholders holding 1% or more of the shares can submit proposals, and the company must notify shareholders of the meeting at least 20 days in advance for annual meetings and 15 days for temporary meetings [11][12] - Voting can occur in person or through authorized representatives, and the company must ensure the voting process is orderly [13][14] Group 3: Decision-Making and Resolutions - Resolutions can be ordinary or special, with ordinary resolutions requiring a simple majority and special resolutions requiring two-thirds approval from attending shareholders [20][22] - Certain significant matters, such as capital changes or major asset transactions, require special resolutions [22][23] - The company must announce the results of the voting and resolutions promptly after the meeting [20][23] Group 4: Related Party Transactions - Related party transactions exceeding 30 million yuan or 5% of the company's net assets must be submitted for shareholders' approval [4][5] - Shareholders with a conflict of interest must abstain from voting on related party transactions [16][17] Group 5: Legal Compliance and Documentation - Legal opinions must be obtained regarding the legality of the meeting procedures and the qualifications of attendees [6] - Meeting records must be maintained for at least 10 years, documenting all proceedings and resolutions [43][44]

南京海辰药业股份有限公司 章 程 目 录 南京海辰药业股份有限公司 章 程 第一章 总 则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》 （以下简称《公司法》）、 《中华人民共和国 证券法》（以下简称《证券法》）和其他有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司（以下 简称"公司"），公司系以发起方式设立。公司在南京市市场监督管理局注册登记， 取得营业执照，统一社会信用代码 913201927453675877。 第三条 公司于 2016 年 12 月经中国证券监督管理委员会核准，首次向社会 公众发行人民币普通股 2,000 万股，于 2017 年 1 月在深圳证券交易所（以下简 称"深交所"）上市。 第四条 公司名称： 中文名称：南京海辰药业股份有限公司 英文名称：Nanjing Hicin Pharmaceutical Co., Ltd. 第五条 公司住所：南京市经济技术开发区恒发路 1 号。 第六条 公司注册资本为人民币 12,000 万元。 第七条 公司为永久存续的股份有限公司。 第八条 董事长为代表公司 ...